Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339111 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
A Phase 3 study of Knee Cartilage Defects, sponsored by Medipost.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 13
- Study locations
NCT07339111 is a Phase 3 study of Knee Cartilage Defects that is actively recruiting participants, run by Medipost. The registered enrollment target is 300 participants. The trial reports 13 study locations across 8 states.
The verdict
NCT07339111, a Phase 3 study of Knee Cartilage Defects, is actively recruiting participants, sponsored by Medipost.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 13
- Study locations
Study Summary
To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator of debridement in Subjects with knee cartilage lesions and osteoarthritis. This trial is intended to provide evidence of the superiority of CARTISTEM® to reduce knee pain and improve knee function compared to debridement for Subjects with knee cartilage lesions and osteoarthritis at 2-years post-treatment. Additionally, this trial is intended to intended to explore whether CARTISTEM® may have disease-modifying effects on osteoarthritis progression through the use of semi-quantitative MRI assessment.
Conditions Studied
Interventions
- BIOLOGICAL CARTISTEM® + Debridement
- PROCEDURE Debridement
Study Locations (13)
Texas
- Zenos Clinical Research - Dallas
- Memorial Hermann Center - Houston
- HD Research Corp. - Houston
- Flourish Research San Antonio - San Antonio
California
- TriWest Research Associates - El Cajon
- Horizon Clinical Research - La Mesa
- Source Healthcare - Santa Monica
Alabama
- Flourish Research Birmingham - Birmingham
Arizona
- AZ Orthopedic - Tempe
Colorado
- Steamboat Orthopaedic and Spine Institute - Steamboat Springs
New Jersey
- Curalta Clinical Trials - Westwood
North Carolina
- West Clinical Research - Morehead City
Utah
- JBR Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07339111
The ClinicalTrials.gov registry entry for NCT07339111 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medipost, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Knee Cartilage Defects appearing as the primary indexed condition, and to 2 interventions - of which CARTISTEM® + Debridement is the first listed.
NCT07339111 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07339111 about?
NCT07339111 is a clinical study titled "Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis". To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator of debridement in Sub...
What is the current status of trial NCT07339111?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-03-11. Estimated completion is 2029-06-30.
What conditions does trial NCT07339111 study?
This clinical trial studies the following conditions: Knee Cartilage Defects.
What interventions are being tested in trial NCT07339111?
The interventions under investigation include: CARTISTEM® + Debridement (BIOLOGICAL), Debridement (PROCEDURE).
Who is sponsoring clinical trial NCT07339111?
This trial is sponsored by Medipost, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339111 being conducted?
This trial has 13 study locations across Alabama, Arizona, California, Colorado, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.